However, the findings need to be interpreted with caution because the study does not account for the lag time between exposure and dementia, which may explain why multiple drugs were found to be protective against the condition. Moreover, medications play a role in reducing neuroinflammation, which is associated with reduced cognitive function and can lead to dementia. The researchers note that GLP-1 RAs may affect dementia because they improve the condition-related risk factors, such as glycated hemoglobin, body weight, systolic blood pressure, and cardiovascular disease. During the five-year follow-up, the group taking GLP-1 RAs had a lower rate of developing dementia compared to the placebo group.
Patients with diabetes are at a 1.6 times higher risk of developing dementia, especially vascular dementia, compared to people without the condition.Ī large 2022 study published in the journal Alzheimer's & Dementia: Translational Research & Clinical Interventions looked at exposure to liraglutide and semaglutide in patients with diabetes.
Semaglutide, which is sold by the brand names Ozempic and Wegovy, recently took the United States by storm after celebrities admitted using these drugs for weight loss.Īnecdotal evidence suggests that GLP-1 RAs can also be useful in treating addictions, whereas some studies indicate that they can be used for dementia prevention. The GLP-1 RAs class of medications includes semaglutide and liraglutide, which may be used to regulate glucose levels, weight loss, and reduce the risk of cardiovascular disease. GLP-1 RAs or glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are the drugs that work by mimicking the GLP-1 hormone that is naturally produced in the gut after a meal and is involved in stimulating insulin release.
0 kommentar(er)
